IN2014CH00391A - - Google Patents

Info

Publication number
IN2014CH00391A
IN2014CH00391A IN391CH2014A IN2014CH00391A IN 2014CH00391 A IN2014CH00391 A IN 2014CH00391A IN 391CH2014 A IN391CH2014 A IN 391CH2014A IN 2014CH00391 A IN2014CH00391 A IN 2014CH00391A
Authority
IN
India
Prior art keywords
cellular immunity
peptide
cancer
composition
subject
Prior art date
Application number
Other languages
English (en)
Inventor
Katsuyuki Okubo
Yoshiki Maeda
Arimichi Okazaki
Daisuke Asari
takuya Shishido
Mitsuhiko Hori
Haruo Sugiyama
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Publication of IN2014CH00391A publication Critical patent/IN2014CH00391A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IN391CH2014 2013-02-05 2014-01-29 IN2014CH00391A (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013020906 2013-02-05

Publications (1)

Publication Number Publication Date
IN2014CH00391A true IN2014CH00391A (enExample) 2015-04-03

Family

ID=50028737

Family Applications (1)

Application Number Title Priority Date Filing Date
IN391CH2014 IN2014CH00391A (enExample) 2013-02-05 2014-01-29

Country Status (8)

Country Link
US (1) US10449144B2 (enExample)
EP (1) EP2762159A1 (enExample)
JP (1) JP6512568B2 (enExample)
KR (1) KR20140100419A (enExample)
CN (1) CN103961307B (enExample)
CA (1) CA2841016A1 (enExample)
IN (1) IN2014CH00391A (enExample)
RU (1) RU2687144C2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2565201B1 (en) 2005-10-17 2014-11-26 Sloan-Kettering Institute For Cancer Research WT1 HLA class II-binding peptides and compositions and methods comprising same
EP3117836A1 (en) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and uses thereof
AU2013207669C1 (en) 2012-01-13 2018-05-31 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
ES2655031T3 (es) * 2012-07-02 2018-02-16 Sumitomo Dainippon Pharma Co., Ltd. Preparación transdérmica de péptido antigénico del cáncer
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
PT2945647T (pt) 2013-01-15 2020-11-26 Memorial Sloan Kettering Cancer Center Péptidos imunogénicos wt-1 e métodos de uso dos mesmos
US10449144B2 (en) 2013-02-05 2019-10-22 Nitto Denko Corporation WT1 peptide cancer vaccine composition for transdermal administration
IN2014CH00393A (enExample) * 2013-02-05 2015-04-03 Nitto Denko Corp
JP6294868B2 (ja) 2013-03-12 2018-03-14 大日本住友製薬株式会社 液体水性組成物
CN106687138B (zh) * 2014-09-03 2021-10-15 日东电工株式会社 包含双膦酸盐剂的细胞性免疫用疫苗药物组合物
TW201618790A (zh) * 2014-10-02 2016-06-01 Nitto Denko Corp 經皮投與用疫苗醫藥組合物

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
PT1103564E (pt) 1998-07-31 2009-03-13 Int Inst Cancer Immunology Inc Antigénios de cancro com base no produto do gene supressor de tumor wt1
IL127331A0 (en) 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
US20030082194A1 (en) * 2000-02-22 2003-05-01 Alexander Gaiger Compositions and methods for diagnosis and therapy of malignant mesothelioma
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
RU2192884C2 (ru) * 2000-11-09 2002-11-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Вакцина для стимуляции противоопухолевого иммунитета
US20040097703A1 (en) 2001-03-22 2004-05-20 Haruo Sugiyama Wt1 modified peptide
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
JP4365784B2 (ja) * 2002-06-12 2009-11-18 株式会社癌免疫研究所 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
EP1548028B1 (en) 2002-09-20 2009-09-09 International Institute of Cancer Immunology, Inc. Substituted type peptides of wt1
US20050215501A1 (en) * 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
PL2071028T3 (pl) 2003-11-05 2012-06-29 Int Inst Cancer Immunology Inc Pochodzący z WT1 peptyd antygenowy wiążący się z HLA-DR
US8562988B2 (en) * 2005-10-19 2013-10-22 Ibc Pharmaceuticals, Inc. Strategies for improved cancer vaccines
CA2560058C (en) 2004-03-15 2011-10-18 David K.R. Karaolis A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
EP2186896B1 (en) 2004-03-31 2015-11-04 International Institute of Cancer Immunology, Inc. Cancer antigen peptides derived from WT1
DE102004049223A1 (de) * 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
EP1782826A1 (en) 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
RU2424247C2 (ru) 2005-11-30 2011-07-20 Интернэшнл Инститьют Оф Кэнсер Иммьюнолоджи, Инк. Пептид, индуцирующий цитотоксические т-клетки (цтл), способ индукции цтл, антитело, связывающееся с этим пептидом, применение пептида в фармацевтической композиции и для лечения или предупреждения рака, антигенпредставляющая клетка
US20100003287A1 (en) * 2005-12-01 2010-01-07 The Provost, Fellows And Scholars Of The Coll. Of The Holy And Undivided Trinity Of Queen Elizabeth Compositions and Methods Relating to Treatment of Cancer and Infectious Diseases
DK2518149T3 (en) 2006-02-22 2016-01-11 Int Inst Cancer Immunology Inc HLA-A * 3303-LIMITED WT1 PEPTIDE AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME
US20080112974A1 (en) 2006-09-08 2008-05-15 Duotol Ab Method for inducing mucosal humoral and cell-mediated immune responses by sublingual administration of antigens
JP4925039B2 (ja) * 2006-09-21 2012-04-25 日東電工株式会社 糖材料の調製方法ならびに糖材料、糖材料を含むマイクロニードルおよびマイクロニードルをそなえてなる経皮製剤
US7935350B2 (en) * 2006-12-14 2011-05-03 Antigen Express, Inc. Ii-key/Her-2/neu hybrid cancer vaccine
CN101573448B (zh) 2006-12-28 2012-07-11 株式会社癌免疫研究所 Hla-a*1101限制的wt1肽及含有其的药物组合物
WO2008093772A1 (ja) * 2007-01-31 2008-08-07 Hisamitsu Pharmaceutical Co., Inc. 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
KR101610664B1 (ko) * 2007-12-05 2016-04-08 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 백신 조성물
PT2119726E (pt) * 2008-05-14 2015-03-30 Immatics Biotechnologies Gmbh Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
AR076349A1 (es) * 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
EP2498795B1 (en) 2009-10-12 2016-12-07 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Granulysin in immunotherapy
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201009222D0 (en) * 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
US10449144B2 (en) 2013-02-05 2019-10-22 Nitto Denko Corporation WT1 peptide cancer vaccine composition for transdermal administration
EP2762155B1 (en) * 2013-02-05 2020-03-11 Nitto Denko Corporation Vaccine Composition
IN2014CH00393A (enExample) * 2013-02-05 2015-04-03 Nitto Denko Corp
KR20140100415A (ko) * 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 경피 투여용 백신 조성물
CN103961698A (zh) 2013-02-05 2014-08-06 日东电工株式会社 经皮或粘膜给予用疫苗组合物

Also Published As

Publication number Publication date
US10449144B2 (en) 2019-10-22
CN103961307B (zh) 2019-11-29
US20140220055A1 (en) 2014-08-07
JP2014169277A (ja) 2014-09-18
CA2841016A1 (en) 2014-08-05
KR20140100419A (ko) 2014-08-14
RU2014102936A (ru) 2015-08-10
EP2762159A1 (en) 2014-08-06
JP6512568B2 (ja) 2019-05-15
RU2687144C2 (ru) 2019-05-07
CN103961307A (zh) 2014-08-06

Similar Documents

Publication Publication Date Title
IN2014CH00391A (enExample)
CY1123563T1 (el) Ανοσογονικα wt-1 πεπτιδια και μεθοδοι χρησης αυτων
CY1120862T1 (el) Παραγοντες επαγωγης αποπτωσης για τη θεραπευτικη αγωγη καρκινου και ανοσων και αυτοανοσων ασθενειων
MX371187B (es) Péptidos terapéuticos.
MX2023000320A (es) Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion.
IN2014CH00395A (enExample)
IN2014CH00393A (enExample)
MD4733B1 (ro) Anticorpi anti-TIGIT
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
IN2014CH00396A (enExample)
MX2021013837A (es) Enfoque de inmunoterapias de combinacion para el tratamiento del cancer.
MX384192B (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
SG10201903119QA (en) Polypeptide vaccine
MX386234B (es) Vacuna para la malaria.
MX377729B (es) Métodos para tratamiento del melanoma.
MX383893B (es) Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar el cáncer.
MX2016014414A (es) Vacuna de peptido que comprende un peptido ras mutante y un agente quimioterapeutico.
MX2017004897A (es) Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer.
SG10201808746QA (en) Methods for enhancing the efficacy of a tumor-directed immune response
MY191539A (en) Streptococcal vaccine
MX2021010886A (es) Uso de medicamentos para disminuir la evolucion de la enfermedad de parkinson.
MX2016011295A (es) Terapia para cancer con anticuerpos anti-met en combinacion con anti-vegfr2.
ZA202503388B (en) Semaglutide in medical therapy
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
IN2014CH00386A (enExample)